At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, and 3 other interventions for Recurrent Melanoma and 4 related conditions. Completed, enrolled 49 participants across 8 sites.
Detailed Summary
This phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. Molecularly targeted therapy works by treating patients with substances that kill cancer cells by targeting key molecules involved in cancer cell growth.
Study Details
Timeline
Interventions
Undergo collection of tissue and blood samples
molecularly targeted therapy, MEK 162 therapy
Correlative studies
Ancillary studies